GLP-1 Receptor Agonists in Breast Cancer: 5 Key Clinical Takeaways

Obesity and weight gain following a breast cancer diagnosis are well-established risk factors for increased breast cancer-specific and all-cause mortality. As glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and newer dual- or tri-receptor agonists (incretin mimetics) redefine metabolic health management, oncology clinicians increasingly face questions about their use during and after active cancer treatment.

At the 43rd Miami Breast Cancer Conference, Neil M. Iyengar, MD, provided a comprehensive overview of the “Metabolic Insights and Clinical Implications” of these agents.¹

He concluded by noting a draft statement from the upcoming European Society for Medical Oncology (ESMO) guidelines. The guidelines state, “GLP-1 RAs may be considered for weight-loss in patients who have completed cancer therapy and may be considered with caution for patients on stable endocrine-based cancer therapies based on limited observational safety data.” They also say, “GLP-1 RAs cannot be recommended currently for patients receiving or initiating chemotherapies and/or immunotherapies due to lack of safety and outcomes data.”

Iyengar is director of Survivorship Services at Winship Cancer Institute of Emory University, a clinical member of Winship’s Glenn Family Breast Center, an associate professor and co-director of the Breast Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, and co-editor-in-chief of the journal ONCOLOGY®.

1. Post-Diagnosis Weight Gain Significantly Increases Mortality Risk

The rationale for aggressive weight management in breast cancer is rooted in its prognostic impact. Data presented by Iyengar emphasized that weight gain following diagnosis, calculated over an average of 1.5 years, is associated with increased mortality.²

• Meta-analyses involving over 12 studies confirm that weight gain increases both breast cancer-specific and all-cause mortality.
• Large-scale trials like the Women's Health Initiative (WHI) demonstrate that a 5% or greater weight loss is associated with a 12% reduction in obesity-associated cancers (HR, 0.88; 95% CI, 0.80-0.98).³
• Clinical interventions, ranging from lifestyle modifications in the Look AHEAD RCT post-hoc analysis to bariatric surgery in the SPLENDID matched cohort study, have shown varying degrees of success in reducing cancer risk, with bariatric surgery achieving up to a 32% reduction with obesity-related cancer (HR, 0.68; 95% CI, 0.53-0.87).^4,5

2. GLP-1 RAs May Improve Survival Outcomes in Breast Cancer Survivors

Emerging retrospective data suggest that GLP-1 RAs do more than just manage weight; they may positively influence survival when assessing incretin mimetics in a post-diagnosis setting.

• Weight Management: In a retrospective study at Memorial Sloan Kettering Cancer Center (MSKCC), patients with stage 0 to IV breast cancer on GLP-1 RAs for a median of 20 months achieved a mean weight change of –6.2 kg (95% CI, –6.2 to –2.1), which showed a 5% relative weight reduction.⁶
• Overall Survival (OS): Data from MD Anderson Cancer Center showed that patients on GLP-1 RAs had a significantly higher median OS compared with controls (median not reached with GLP-1 RAs vs 24.1 years for control; P <.0001).⁷
• Endocrine Therapy Interaction: The MD Anderson Cancer Center retrospective observational cohort study also found tamoxifen or aromatase inhibitor (AI) use is typically associated with weight gain of +2.3 kg (P = .037).

3. Diabetes and GLP-1 RA Use in Cancer Incidence

Beyond weight loss, GLP-1 RAs appear to have a protective effect against cancer development and progression.

• Comparative Risk: In patients with Type 2 Diabetes, GLP-1 RA use was associated with a 7% lower cancer incidence compared with DPP4 inhibitors.⁸
• Broad Benefits: In a broader population with or without diabetes, GLP-1 RA use was associated with a 17% lower cancer incidence.⁹

4. Caution is Required During Active Chemotherapy and Immunotherapy

While the benefits in the survivorship setting are promising, Iyengar highlighted a note of caution for patients currently undergoing intensive active treatment.

• Neoadjuvant Setting: Specifically, caution is advised for patients using GLP-1 RAs during neoadjuvant regimens like the phase 3 KEYNOTE-522 trial (NCT03036488).¹⁰
• Draft ESMO Guidelines: Upcoming guidelines from ESMO state that GLP-1 RAs cannot currently be recommended for patients initiating or receiving chemotherapy or immunotherapy due to a lack of safety and outcomes data.
• Stable Therapy: Use may be considered with caution for patients on stable endocrine-based therapies, provided there is close monitoring.

5. Managing Discontinuation: The 20-Week Taper Strategy

A significant challenge with GLP-1 RA therapy is the rate of weight regain once the medication is stopped.¹¹

• Weight Rebound: Patients typically experience a 7% to 12% weight rebound following GLP-1 RA discontinuation.
• Tapering Protocol: To mitigate this, Iyengar suggested considering a dose taper over at least 20 weeks.
• Reinitiation Criteria: Clinicians should consider increasing the dose or reinitiating therapy if a patient experiences more than 5% weight regain.

References

1. Iyengar NM. GLP-1 receptor agonists and breast cancer: metabolic insights and clinical implications. Presented at: 43rd Miami Breast Cancer Conference; March 5-8, 2026.
2. Playdon MC, Bracken MB, Sanft TB, Ligibel JA, Harrigan M, Irwin ML. Weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis. J Natl Cancer Inst. 2015;107(12):djv275. doi:10.1093/jnci/djv275
3. Luo J, Hendryx M, Manson JE, et al. Intentional Weight Loss and Obesity-Related Cancer Risk. JNCI Cancer Spectr. 2019;3(4):pkz054. Published 2019 Aug 9. doi:10.1093/jncics/pkz054
4. Look AHEAD Research Group, Yeh HC, Bantle JP, et al. Intensive weight loss intervention and cancer risk in adults with type 2 diabetes: analysis of the Look AHEAD Randomized Clinical Trial. Obesity (Silver Spring). 2020;28(9):1678-1686. doi:10.1002/oby.22936
5. Aminian A, Wilson R, Al-Kurd A, et al. Association of bariatric surgery with cancer risk and mortality in adults with obesity. JAMA. 2022;327(24):2423-2433. doi:10.1001/jama.2022.9009
6. Shen S, Bethina Liu, Chad Fanti, et al. GLP-1 receptor agonist use and weight change in patients with breast cancer. Oncology (Williston Park). 2025;null(7):294-296. doi:10.46883/2025.25921046
7. Sukumar JS, Raghavendra AS, Pasyar S, et al. Weight loss patterns and clinical outcomes of glp1 receptor agonists in breast cancer survivors. Cancer Res Commun. 2026;6(3):447-455. doi:10.1158/2767-9764.CRC-25-0554
8. Mavromatis LA, Surapaneni A, Mehta S, et al: Glucagon-like peptide-1 receptor agonists and incidence of obesity-related cancer in adults with diabetes: A target-trial emulation study. 2025 ASCO Annual Meeting. Abstract 10507. Presented at press briefing May 21, 2025.
9. Dai H, Li Y, Lee YA, et al. GLP-1 receptor agonists and cancer risk in adults with obesity. JAMA Oncol. 2025;11(10):1186-1193. doi:10.1001/jamaoncol.2025.2681
10. Gruber J, Soares dos Santos B, Marção M, et al. GLP-1 Targeting Agents Impair Chemoimmunotherapy Effectiveness in Triple-Negative Breast Cancer. Preprint. Research Square. Accessed March 6, 2026. https://tinyurl.com/2j2h77ud
11. Mehrtash F, Dushay J, Manson JE. Integrating Diet and Physical Activity When Prescribing GLP-1s-Lifestyle Factors Remain Crucial. JAMA Intern Med. 2025;185(9):1151-1152. doi:10.1001/jamainternmed.2025.1794